CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net income (loss)	$ 152,000	$ (10,927,000)
Adjustments to reconcile net income (loss) to cash, cash equivalents, and restricted cash used in operating activities:
Depreciation and amortization	4,411,000	3,341,000
Amortization of debt issuance costs	2,444,000	53,000
Goodwill impairment charges	9,944,000	0
Share-based compensation	27,683,000	24,535,000
Decrease in fair value of liability classified warrants	(1,843,000)	(3,686,000)
Decrease in fair value of liability classified earnouts	(59,215,000)	(24,891,000)
Decrease in fair value of liability classified conversion option derivatives	(24,200,000)	0
Unrealized (gain) loss on investments	378,000	0
Accretion of discount on investment securities	(1,020,000)	0
Deferred taxes	(263,000)	(1,242,000)
Gain on loan forgiveness	(183,000)	(4,957,000)
Bad debt expense (recovery)	476,000	(417,000)
Loss on disposal of property and equipment	21,000	0
Changes in operating assets and liabilities, net of business combinations:
Accounts receivable	(20,285,000)	(2,195,000)
Inventories	(1,732,000)	(1,842,000)
Other receivables	620,000	(792,000)
Prepaid expenses	4,282,000	(9,091,000)
Operating lease right-of-use assets	5,404,000
Other assets	(157,000)	(198,000)
Accrued expenses and other current liabilities	2,349,000	(3,084,000)
Income taxes payable	123,000	(1,012,000)
Accounts payable	(6,187,000)	2,916,000
Current and long-term operating lease liabilities	(3,801,000)	0
Other non-current liabilities	(1,157,000)	809,000
Net cash, cash equivalents, and restricted cash used in operating activities	(61,756,000)	(32,680,000)
Cash flows from investing activities:
Purchases of property and equipment	(5,529,000)	(2,847,000)
Purchases of intangible asset in practice acquisitions	0	(200,000)
Cash paid for practice acquisitions, net	(8,577,000)	(9,107,000)
Purchases of marketable securities/investments	(117,508,000)	0
Net cash, cash equivalents, and restricted cash used in investing activities	(131,614,000)	(12,154,000)
Cash flows from financing activities:
Proceeds from recapitalization transaction	0	333,946,000
Transaction costs	0	(33,145,000)
Payments as a result of recapitalization transaction	0	(167,510,000)
Proceeds from issuance of long-term debt	110,000,000
Transactions costs related to issuance of long-term debt	(3,663,000)	0
Proceeds from financing of insurance payments	0	8,429,000
Payments made for financing of insurance payments	(5,009,000)	(409,000)
Payment of deferred consideration liability for acquisition	(509,000)	(50,000)
Principal payments on long-term debt	0	(7,219,000)
Principal payments on financing leases	(58,000)
Principal payments on financing leases		(32,000)
Payments for Repurchase of Common Stock	(9,000,000)	0
Common stock issued for options exercised	858,000	0
Taxes for common stock net settled	(413,000)	0
Issuance of Legacy TOI preferred stock	0	20,000,000
Net cash, cash equivalents, and restricted cash provided by financing activities	92,206,000	154,010,000
Net (decrease) increase in cash, cash equivalents, and restricted cash	(101,164,000)	109,176,000
Cash, cash equivalents, and restricted cash at beginning of period	115,174,000	5,998,000
Cash, cash equivalents, and restricted cash at end of period	14,010,000	115,174,000
Cash paid for:
Income taxes	150,000	1,727,000
Interest	224,000	275,000
Supplemental disclosure of noncash investing and financing activities:
Reclassification of public warrant derivative liability related to the recapitalization transaction into equity	0	10,580,000
Fair value of assets acquired as part of acquisition (except for cash and goodwill)	0	1,175,000
Deferred consideration as part of practice acquisitions	0	4,468,000
Discount on senior secured convertible note	$ 28,160,000	$ 0